InvestorsHub Logo
Followers 62
Posts 7557
Boards Moderated 1
Alias Born 01/02/2003

Re: None

Friday, 06/10/2022 2:19:14 PM

Friday, June 10, 2022 2:19:14 PM

Post# of 426487
The failure of the expensive Strength study conducted by Nissen for AZN was good for Amarin in that it eliminated Epanova as a competitor to Vascepa in the Rx of CVD...but it embittered Dr. Nissen, who somehow blamed Amarin for the failure of his pet project and circulated false rumors that a mineral oil placebo was the reason for the Vascepa "fish oil" success in R-IT.

Dr. Nissen persists in spreading this disproven mantra to this day, even traveling to England to repeat it at the NICE meeting.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News